Significance of interleukin-1β and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases

American Journal of Gastroenterology

Volumn 92, Issue 7, 1997, Pages 1164-1169

  Heresbach, D ^a   Alizadeh, M ^b   Dabadie, A ^b   Le Berre, N ^b   Colombel, J F ^b   Yaouanq, J ^b   Bretagne, J F ^b   Semana, G ^b  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1; INTERLEUKIN RECEPTOR;

ARTICLE; CHROMOSOME 2; ENTERITIS; GENE AMPLIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; ADULT; ALLELE; CROHN DISEASE; DRUG ANTAGONISM; FEMALE; GENETICS; HOSPITALIZATION; MALE; ULCERATIVE COLITIS;

ADULT; ALLELES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1; MALE; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN; SEVERITY OF ILLNESS INDEX;

EID: 0030610480     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-4.
2. Satsangi J, Parkes M, Louis E, et al. Systematic genome wide search for susceptibility genes in inflammatory bowel disease: Evidence for the involvement of non-HLA genes. Nat Genet 1996;14:199-202.
3. Hyams JS, Fitzgerald JE, Wyzga N, et al. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci 1994;39:1893-9.
4. Ligumsky M, Simon PL, Karmeli F, et al. Role of IL-1 in inflammatory bowel disease: Enhanced production during active disease. Gut 1990; 3:686-9.
5. Nishiyama T, Mitsuyama K, Toyonaga A, et al. Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease. Digestion 1994;55:368-73.
6. Brynskov J, Tvede N, Andersen CB, et al. Increased concentrations of interleukin-1, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992;33:55-8.
7. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-, interleukin-1 and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
8. Cominelli F, Nast CC, Clark BD, et al. Interleukin-1 gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990;86:972-80.
9. Sartor R, Holt L, Bender D, et al. Prevention and treatment of experimental enterocolitis with a recombinant interleukin-1 receptor antagonist. Gastroenterology 1991;110:A613 (abstract).
10. Andus T, Gross V, Scholmerich J. Elevated circulatory interleukin-1 receptor antagonist levels in serum of patients with active Crohn's disease and ulcerative colitis. Gastroenterology 1995;104: A660 (abstract).
11. Mitsuyama K, Toyonaga A, Sasaki E, et al. Role of interleukin-1 receptor antagonist in inflammatory bowel disease (IBD). Gastroenterology 1993;104: A747 (abstract).
12. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
13. Andus T, Daig R, Lock G, et al. Balance between pro- and antiinflammatory cytokines in the colonic mucosa in inflammatory bowel diseases (IBD). Gastroenterology 1995;108:A770 (abstract).
14. Casini-Raggi V, Kam L, Chong YJT, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: A novel pathogenetic mechanism. J Immunol 1995;154:2434-40.
15. Gilberts ECAM, Greenstein AJ, Katsel P, et al. Molecular evidence for two forms of Crohn's Disease. Proc Natl Acad Sci USA 1994;91: 12721-4.
16. Hendel J, Nielsen OH, Madsen S, et al. A simple filter-paper technique allows detection of mucosal cytokine levels in vivo ulcerative colitis: Interleukin-1 and interleukin-1-receptor antagonist. Dig Dis Sci 1996; 41:1775-9.
17. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-42.
18. Andus T, Caesar I, Vogl D, et al. Association of HLA-DR15, P-ANCA and IL-1 receptor antagonist allele 2 with ulcerative colitis. Gastroenterology 1995;108:A770 (abstract).
19. Duerr RH, Tran T. Association between ulcerative colitis and a polymorphisms intron 2 of the interleukin-1 receptor antagonist gene. Gastroenterology 1995;108:A812 (abstract).
20. Tountas NA, Karn L, Digiovine FS, et al. Genetic association between allele 2 of IL-1 receptor antagonist (IL-1ra) and ulcerative colitis (UC) in a Los Angeles-based Hispanic population. Gastroenterology 1995; 108: A930 (abstract).
21. Bioque G, Bouma G, Crusius JBA, et al. Evidence for genetic heterogeneity in IBD: 1: The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenterol Hepatol 1996;8:105-10.
22. Satsangi LE, Roussomoustakaki M, Belaiche J, et al. Cytokine gene polymorphisms in inflammatory bowel disease. Gut 1996;705-10.
23. Bioque G, Crusius JBA, Koutroubakis I, et al. Allelic polymorphism in IL-1b and IL-1 receptor antagonist (IL-1ra) genes in inflammatory bowel disease. Clin Exp Immunol 1995;102:379-83.
24. Tountas NA, Yang H, Coulter DI, et al. Increased carriage of allele 2 of IL-1 receptor antagonist (IL-1ra) in Jewish populations: The strongest known genetic association in ulcerative colitis. Gastroenterology 1996;110:5:A1029 (abstract).
25. Digiovine FS, Takhsh E, Blakemore AIF, et al. Single base polymorphism at -511 in the human interleukin-1β gene. Hum Mol Genet 1992;1:450.
26. Pociot F, Molvig J, Wogensen L, et al. A Taq1 polymorphism in the human interleukin-1β (IL-1β) gene correlated with IL-1β secretion in vitro. Eur J Clin Invest 1992;22:396-402.
27. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24(suppl 170):2-6.
28. Le Berre N, Heresbach D, Kerboal M, et al. Histological discrimination of idiopathic inflammatory bowel disease from other types of colitis. J Clin Pathol 1995;48:749-53.
29. Truelove SC, Willoughby CP, Lee EG, et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2:1087-8.
30. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological and endoscopie picture of attacks of Crohn's evolution on prednisolone. Gastroenterology 1990;98:811-8.
31. Munkholm P, Langholz E, Davidson M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35: 360-2.
32. Tarlow JK, Blakemore AIF, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-base pair tandem repeat. Hum Genet 1993;91:403-4.
33. Mathiuz PL, Ihde D, Piazza A, et al. New approaches to the population genetics and aggregation analysis of the HLA system. In: Terasaki PI, ed. Histocompatibility Testing. Copenhagen: Munksgaard, 1970: 193-205.
34. Cook MG, Dixon MF. Analysis of the reliability of detection and diagnostic value of various pathological features in Crohn's disease and ulcerative colitis Gut 1973;14:255-62.
35. Leideinius M, Kellokumpu I, Linden H, et al. The true extent of ulcerative colitis? A radiological, endoscopic and histological study. APMIS 1994;102:950-5.
36. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994;107:3-13.
37. Langholz E, Munkholm P, Davidsen M, et al. Changes in extend of ulcerative colitis: A study on the course and prognostic factors. Scand J Gastroenterol 1996;31:260-6.
38. Arend WP, Smith MF, Janson RW, et al. IL-1 receptor antagonist and IL-1 production in human monocytes are regulated differently. J Immunol 1991;147:1530-6.
39. McIntyre KW, Stepan GJ, Kolinsky KD, et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammatory in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991;173:931-3.
40. Danis VA, Millington M, Hyland VJ, et al. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-I receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-10.
41. Andus T, Vogl D, Aschenbrenner E, et al. IL-1ra genotype 2 is associated with reduced IL-1ra in colonic mucosa. Gastroenterology 1996;110:5: A855 (abstract).
42. Dionne S, D'agata ID, Hiscott J, et al. IL-1β and IL-1ra production by IBD colonie explant culture. Gastroenterology 1996;116:65:A772 (abstract).
43. Mandrup-Poulsen T, Pociot F, Molvig J, et al. Monokine antagonism is reduced in patients with IDDM. Diabetes 1994;43:1242-7.
44. Fleis E. Statistical methods for rates and proportions, 2nd ed. New York: J Wiley, 1981.
45. Nicklin MJH, Wiegh A, Duff GW. A physical map of the region encompassing the human interleukin-1a, interleukin-1b, receptor antagonist genes. Genomics 1994;19:382-4.
46. Schreiber S, Bouchard A, Reinking R, et al. Impaired deactivation of intestinal lamina propria macrophages by IL-4 in inflammatory bowel disease. Gastroenterology 1994;106:A769 (abstract).
47. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 1993.261:472-5.
48. Dignass AU, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor β. Gastroenterology 1993;105:1323-32.
49. Kuida K, Lippke JA, Ku G, et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 -converting enzyme. Science 1995; 267:2000-2.